# Creoptix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/creoptix

- Industry: Medical Devices & Equipment
- Headquarters: Switzerland
- Website: www.creoptix.com
- Total disclosed funding: $8.1M
- Latest round: Series C (Sep 30, 2019)
- Investors on record: 2

## About

Creoptix AG is a Swiss company specializing in advanced bioanalytical instruments, particularly for molecular interaction analysis in drug discovery and academic research.Creoptix AG, founded in 2009 in Switzerland, develops bioanalytical instruments, notably the Creoptix WAVE. The company operates from its headquarters in Zurich and has undergone a strategic pivot towards enhancing its product offerings. The founder, Kaspar Cottier, has extensive experience in the life sciences sector. As of January 2022, Creoptix raised CHF 8.000 mn in a Series C funding round led by Swisscanto Invest by Zürcher Kantonalbank, marking the latest investment in the company's growth trajectory. The total amount raised by Creoptix is CHF 8.000 mn, with four deals completed to date, the most recent being on January 11, 2022.Creoptix specializes in the development and provision of advanced bioanalytical instruments focused on molecular interaction analysis, primarily through its flagship product, the Creoptix WAVE. This state-of-the-art instrument employs proprietary biosensor, microfluidics, and software technologies to deliver high sensitivity and resolution, enabling researchers to study real-time biological interactions involving small molecules, peptides, membrane proteins, biologics, and more. The WAVE is designed to operate effectively even in complex biological environments, such as undiluted serum and plasma, making it a valuable tool for both academic research and industry applications in drug discovery. Creoptix targets a wide array of clients, including pharmaceutical companies, biotechnology firms, and academic institutions, with its products being marketed primarily in North America, Europe, and Asia.Creoptix generates revenue through direct sales of its flagship instrument, the Creoptix WAVE, along with supporting chips and software. The company engages in B2B transactions, primarily supplying products to life sciences research institutions and pharmaceutical companies. Revenue stems from the sale of hardware, with additional income derived from software licenses and support services. Partnerships with academic and industrial entities facilitate access to its products, further driving revenue through collaborative research projects. Pricing structures for its instruments and associated services are tailored to meet the specific needs of its clientele, ensuring comprehensive solutions for molecular interaction analysis.Creoptix AG is focused on developing new products to enhance its offerings, with plans to introduce advancements in molecular interaction analysis technology. The company aims to expand its reach into additional markets across Europe and North America by the end of 2023. Recent funding from the Series C round will support these initiatives, particularly in product development and market penetration efforts. Additionally, in January 2022, Malvern Instruments Ltd. agreed to acquire Creoptix AG, a move that is expected to bolster its operational capabilities and market access.

## Funding rounds

- Series C, Sep 30, 2019, $8.1M — Waters Corporation, Swisscanto

## Investors

- Waters Corporation — Series C
- Swisscanto (https://capitalatlas.ai/funds/swisscanto) — Series C